RPG Life Sciences (RPGLIFE) investor relations material

Business overview and portfolio

• Integrated pharmaceutical company with presence in branded formulations, global generics, and synthetic APIs across 50+ markets.

• Domestic formulations contribute 69% of sales, with leadership in immunosuppressants and nine therapy areas.

• Product portfolio includes strong textbook brands and new launches in chronic and specialty therapies.

• Key therapies include nephrology, rheumatology, oncology, pain management, gastroenterology, and cardio-diabetes.

• Operates three manufacturing facilities and employs over 1,300 people.

Financial performance and growth

• Achieved 8.3% revenue growth and 24.4% EBITDA margin in FY26, with revenue reaching ₹707.5 crore.

• ROE at 21.1% and ROCE at 28.5%, reflecting strong profitability and capital efficiency.

• EPS improved to 69.6, supported by robust operational performance.

• Five-year revenue CAGR of 12.7%, with significant cash reserves of ₹276.5 crore.

• Over ₹185 crore invested in capex over five years, supporting growth and capacity expansion.

Domestic formulations and market position

• Domestic formulations business grew 1.6x faster than the Indian Pharma Market in FY26.

• Ranked 52nd in IPM, up from 58th, and recognized among the fastest-growing pharma companies in India.

• Key brands like Naprosyn recorded 16% growth, with almost all major brands achieving double-digit growth.

• New product launches contributed 4.1% to overall growth.

• Achieved 6.4% volume growth versus IPM's 0.7% in FY26.